San Jose, CA – October 04, 2023 (PRESS RELEASE)
Biomed Industries, Inc.™ (Headquarters: San Jose, California, USA, CEO: Lloyd L. Tran, “Biomed”)
Biomed Industries™, Inc. (Biomed) is gearing up to showcase four pivotal research papers at the Clinical Trials on Alzheimer's Disease (CTAD) International Conference 2023. These papers are set to challenge the amyloid hypothesis and introduce the neurogenesis hypothesis as a novel approach. Moreover, two additional papers will detail the clinical protocols for a combination therapy, involving NA-831 with Aducanumab and Lecanemab respectively, targeting early-onset Alzheimer’s disease (AD).
Featured Papers:
"Amyloid-beta (Aβ) in Alzheimer’s Disease: A Historical Perspective on its Role" by Lloyd Tran and Zung Tran.
"The Neurogenesis Hypothesis: Clinical Trials and Implications of NA-831 for Alzheimer’s and Major Depressive Disorder" by Lloyd Tran and Zung Tran.
"Phase 2 Clinical Protocol: Assessing the Safety and Efficacy of NA-831 in Combination with Aducanumab in Early Alzheimer’s Disease" by Lloyd Tran, Fern Vu, and Markku Kurkinen.
"Phase 3 Clinical Protocol: Evaluating NA-831 and Lecanemab in Treating Early Alzheimer’s Disease" by Lloyd Tran, Fern Vu, and Markku Kurkinen.
In light of recent FDA approvals, it's noteworthy that Aducanumab (2021) and Lecanemab (2023) received the nod based on surrogate biomarkers, despite serious adverse effects and no significant clinical benefits.
Dr. Zung Tran, Biomed's Vice President of Bioinformatics and AI, observed, “The marginal differences between drug and placebo for these treatments underline the pressing need for groundbreaking research directions.”
Taking a pioneering step, Biomed introduces the Neurogenesis Hypothesis, backed by promising Phase 2A clinical results from NA-831, as a potential alternative to the Amyloid hypothesis.
Dr. Lloyd L. Tran, Biomed's Chairman and CSO, remarked, “Even if we can develop drugs that block or reduce amyloid beta, they will not reverse the damage. By the time one can measure the changes of amyloid beta in the brain, it is too late. Our clinical results of NA-831 show that adult neurogenesis in the hippocampus could be a way to partially right that wrong”
He further invited collaboration, saying, "We're eager to join forces with fellow researchers and pharmaceutical firms to chart a course for effective AD treatments.”
With momentum on their side, Biomed will conduct a Phase 2B trial of its new class of drugs and will seek FDA accelerated approval of NA-831 for the treatment of AD.
About Biomed Industries, Inc.
Biomed Industries™, Inc. is a bio-pharmaceutical company committed to the development and commercialization of new drug therapeutics for unmet needs. Biomed is a leading innovator, having discovered a new family of clinical stage drugs for the treatment of Alzheimer's disease and other neurological disorders. The Company is also developing new applications of AI for drug discovery, clinical trials recruitment and execution, and other mission critical areas in the pharmaceutical and medical device industry. For more information, please visit https://www.biomedind.com
CONTACT
Michael Willis
Biomed Industries, Inc.
San Jose, CA 95131 USA
Tel. 800-824-5135
Email: media@biomedind.com
For more news, please visit our News pages. More News
For further information about Biomed Industries, Inc., please contact us. Contact us